china merchants securities

The drug developer will be the second biotech firm to list in Hong Kong without any profits or revenues. It believes that China’s underpenetrated biologics market provides a massive opportunity in the long run.

The regional Chinese lender launches an initial public offering to raise $1.1 billion and looks set to become the third bank classed as a rural financial institution to list in Hong Kong.

Chinese biopharmaceutical firm to list biologics arm in Hong Kong after delisting in New York in 2015. All the signs are it will deliver healthy returns for backers of its privatisation.

Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.

Chinese private hospital operator launches Asia’s first IPO in the new calendar year.

China Datang Group has launched a second attempt to spin-off its energy conservation business as China tightens emissions standards.

After the successful deal, China Resources Group has now listed six of its subsidiaries in Hong Kong.

China's second-largest drug manufacturer to raise funds for expansion amid industry consolidation.

China's eighth largest brokerage by assets achieves mid-range price in the face of challenging markets for brokerage stocks.